Another DeepSeek moment for China's innovative drugs and biotech

On June 17, 2025, China's innovative drugs and biotech fields ushered in an epoch-making milestone! The world's first RWA (real world asset) token project with equity of Chinese innovative drugs and biotech companies as underlying assets was officially launched. This pioneering project not only marks a breakthrough in the global financial and technological fields of the RWA model with equity as the underlying asset, but also attracts global attention due to the disruptive technology developed by its underlying asset companies. It is known as "another DeepSeek moment for China's biotech", symbolizing China's strong rise in the global new drug research and development and biotechnology track. (Token abbreviation: BIOPH, token address: 6Vwi5TYaX7BQNy3L3g4r38TiSm1GhZ7w1nuEx2Ve1Y2t)

One of the core highlights of the project is the AI-NANO new drug innovation and development platform developed by its underlying asset company. This platform completely reshapes the traditional drug development model by deeply integrating the "AI chemical drug screening system" and the "NDSIP delivery system". The AI-NANO platform uses advanced artificial intelligence algorithms to efficiently and accurately screen massive molecular structures, and combines nano-scale precision delivery technology to optimize the absorption and targeting effects of drugs in the human body. In theory, the platform can improve most of the existing drugs in the world, significantly reduce the adverse drug reaction rate, and greatly improve the efficacy. Compared with the traditional R&D model, the AI-NANO platform shortens the R&D cycle to one-third of the traditional one, reduces the R&D cost by more than 40%, and increases the success rate of drug R&D to 2.5-5 times that of the traditional model. Thanks to this, the AI-NANO platform provides new possibilities for conquering a variety of complex diseases, especially in frontier fields such as cancer, neurodegenerative diseases, autoimmune diseases and rare diseases.

The launch of this project not only demonstrates China's technological leadership in the global biomedicine field, but also opens up a new investment track for the global capital market. Through the innovative application of blockchain technology, the project digitizes the equity of China's leading innovative biopharmaceutical companies into RWA tokens, providing global investors with a safe, liquid and highly transparent participation channel. This model not only provides international investors with the opportunity to share the dividends of China's rapid growth in biotechnology, but also promotes the innovation of financing mechanisms in the global biopharmaceutical industry and accelerates the global promotion and application of cutting-edge technologies. Industry analysts pointed out that the launch of RWA tokens will further enhance the competitiveness of Chinese biotechnology companies in the international market, while attracting more global capital and technological resources to flow into China.

The wide application potential of the AI-NANO platform has been highly recognized by the international academic and industrial communities. Its breakthrough results in preclinical research, including significantly improving drug efficacy and reducing side effects, have been verified by multiple international authoritative organizations. In addition, the platform is highly flexible and can quickly adapt to the research and development needs of different disease areas, providing strong technical support for the development of personalized medicine and precision medicine. Experts predict that as the AI-NANO platform matures further, it is expected to become the core infrastructure for global new drug research and development, completely changing the competitive landscape of the pharmaceutical industry.

About the underlying asset company

The underlying asset company is a biopharmaceutical technology research and development company that has been established in China for ten years with an innovative drug research and development platform as its core competitiveness. It is committed to becoming a pioneer in an integrated drug integration research and development system and has the feasibility of optimizing and upgrading most of the drugs on the market. It has reserved multiple new molecular entities (new molecular entities: active ingredients that have never been approved or sold as drugs) and innovative drugs with independent intellectual property rights. It will continue to optimize and integrate the latest technologies, continuously extend the scope of application, and strive to create high-quality, affordable innovative drugs for patients.

About the RWA token project

The project is led by an international professional team. Relying on advanced blockchain technology, the equity of China's innovative biopharmaceutical companies will be converted into RWA tokens to ensure the transparency, traceability and high liquidity of assets. The project aims to provide global investors with a unique opportunity to participate in the rapid development of China's biotechnology industry through an innovative model of digital assets, while promoting global cooperation and technical exchanges in the field of biomedicine. According to the project team, the underlying asset company is currently in the process of listing on the Nasdaq in the United States, and is expected to be completed within 2025, with great investment value and growth space.

About the future of China's biotechnology industry

The launch of the RWA token project is an important step for China's biotechnology industry to move towards globalization. In recent years, China's rapid progress in artificial intelligence, biotechnology and blockchain has injected strong momentum into the biopharmaceutical industry. The successful development and application of the AI-NANO platform has further consolidated China's leading position in the field of global innovative drugs and biotechnology, indicating that China will become the core engine of global pharmaceutical innovation in the next decade.